文献速递其他结缔组织病

抗Ro52与抗Ro60双阳性与系统性硬化症更严重的器官受累及疾病进展相关

Dual positivity for Anti-Ro52 and Anti-Ro60 antibodies is linked to greater organ involvement and disease progression in systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2025-08-12

单中心观察性研究纳入379例系统性硬化症患者,按抗Ro52/TRIM21和抗Ro60/SSA血清学状态分四组。双阳性占12.7%,多变量分析显示双阳性独立增加间质性肺病、肺动脉高压、指端溃疡和胃肠道受累风险,无进展生存更差。

要点

  • 双阳性患者占12.7%,间质性肺病发生率79.2%、肺动脉高压25.0%、指端溃疡41.7%、胃肠道症状79.2%。
  • 双阳性独立增加间质性肺病(校正OR=2.27)、肺动脉高压(校正OR=2.24)、指端溃疡(校正OR=3.12)和胃肠道受累(校正OR=2.28)风险。
  • 双阳性患者无进展生存更差,总体进展校正HR=1.90,间质性肺病进展校正HR=2.20。

核心结论

  • 抗Ro52和抗Ro60双阳性识别出系统性硬化症中器官受累严重、疾病进展加速(尤其间质性肺病)的独立亚组。
  • 作者认为联合抗体检测具有预后价值,并强调对双阳性患者需保持警惕性监测。

研究设计与样本

  • 单中心观察性研究,使用仁济硬皮病纵向队列(Renji-SLOC)数据,纳入379例随访至少1年的系统性硬化症患者。
  • 按血清学状态分为四组:双阴性(Ro52-/Ro60-)、单纯抗Ro52/TRIM21阳性(Ro52+)、单纯抗Ro60/SSA阳性(Ro60+)、双阳性(Ro52+/Ro60+)。
  • 采用多变量逻辑回归和生存分析评估临床特征与疾病进展。

主要发现

  • 379例中双阳性占12.7%(n=48);Ro52阳性患者中43.6%同时Ro60阳性,Ro60阳性患者中62.3%同时Ro52阳性。
  • 双阳性患者间质性肺病发生率79.2%、肺动脉高压25.0%、指端溃疡41.7%、胃肠道症状79.2%。
  • 多变量分析显示双阳性独立增加间质性肺病风险(校正OR=2.27,95%CI=1.02-5.14)、肺动脉高压风险(校正OR=2.24,95%CI=1.03-4.84)、指端溃疡风险(校正OR=3.12,95%CI=1.57-6.20)和胃肠道受累风险(校正OR=2.28,95%CI=1.08-4.81)。
  • 生存分析显示双阳性患者无进展生存显著更差:总体进展校正HR=1.90(95%CI=1.24-2.90),间质性肺病进展校正HR=2.20(95%CI=1.36-3.57),两者p<0.05。

关键数值与推荐

  • 双阳性定义为抗Ro52/TRIM21和抗Ro60/SSA均阳性,占379例系统性硬化症患者的12.7%(n=48)。
  • 双阳性患者间质性肺病发生率79.2%、肺动脉高压25.0%、指端溃疡41.7%、胃肠道症状79.2%。
  • 双阳性与间质性肺病独立相关(校正OR=2.27,95%CI=1.02-5.14)。
  • 双阳性与肺动脉高压独立相关(校正OR=2.24,95%CI=1.03-4.84)。
  • 双阳性与指端溃疡独立相关(校正OR=3.12,95%CI=1.57-6.20)、与胃肠道受累独立相关(校正OR=2.28,95%CI=1.08-4.81)。

临床怎么用

  • 作者认为联合抗体检测具有预后价值,并强调对双阳性患者需保持警惕性监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the distinct and combined effects of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies on the clinical features and prognosis of patients with systemic sclerosis (SSc). METHODS: A single-center observational study was conducted using data from the Renji Scleroderma Longitudinal Cohort (Renji-SLOC), including 379 SSc patients with at least 1 year of follow-up. The patients were categorized into four groups based on serological status: double-negative (Ro52-/Ro60-), isolated anti-Ro52/TRIM21 positive (Ro52+), isolated anti-Ro60/SSA positive (Ro60+), double-positive (Ro52+/Ro60+). Clinical features and disease progression were analyzed using multivariable logistic regression and survival analysis. RESULTS: Among 379 patients, 12.7% (n=48) were double-positive. Notably, 43.6% of Ro52-positive patients were also Ro60-positive, and 62.3% of Ro60-positive patients were Ro52-positive, indicating significant co-occurrence. Double-positive patients exhibited significantly higher rates of ILD (79.2%), PAH (25.0%), digital ulcers (41.7%), and gastrointestinal symptoms (79.2%). Multivariable analysis confirmed that double positivity independently increased risks of ILD (adjusted OR=2.27, 95% CI=1.02-5.14), PAH (adjusted OR=2.24, 95% CI=1.03-4.84), digital ulcers (adjusted OR=3.12, 95% CI=1.57-6.20), and gastrointestinal involvement (adjusted OR=2.28, 95% CI=1.08-4.81). Survival analysis demonstrated significantly worse progression-free survival in double-positive patients (adjusted HR=1.90, 95% CI=1.24-2.90 for overall progression; adjusted HR=2.20, 95% CI=1.36-3.57 for ILD progression, both p<0.05). CONCLUSION: Dual positivity for anti-Ro52 and anti-Ro60 antibodies identifies a distinct SSc subgroup with severe organ involvement and accelerated disease progression, particularly ILD. These findings highlight the prognostic value of combined antibody testing and underscore the need for vigilant monitoring in double-positive patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Yin H, Lin W, Jia C, et al. Dual positivity for Anti-Ro52 and Anti-Ro60 antibodies is linked to greater organ involvement and disease progression in systemic sclerosis. Semin Arthritis Rheum. 2025. PMID: 40819618. doi:10.1016/j.semarthrit.2025.152810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。